Clinical Trials

Overview

Salanersen (BIIB115/ION306)

BIIB115 is an investigational antisense oligonucleotide (ASO) developed by Biogen for the treatment of SMA, that may have the potential to help address additional unmet needs, as well as to be administered at extended dosing intervals.

Method of Action

Like nusinersen, salanersen boosts production of the full-length SMN protein by acting on the SMN2 gene. It uses a new antisense chemistry designed to improve potency, stability, and durability, with the potential to achieve high efficacy and enable once-yearly dosing.

Trial of salanersen

Trial Name
BIIB115
Age:
6 months to 55 years old.
Aim:
To evaluate the safety and tolerability of BIIB115 (IT) bolus injection to healthy male participants (Part A) and to paediatric SMA participants previously treated with onasemnogene abeparvovec (Part B). The secondary objective is to evaluate the pharmacokinetics (PK) of BIIB115 (IT) bolus injection to healthy male participants (Part A) and to paediatric SMA participants who previously received onasemnogene abeparvovec (Part B).
Status:
Active, not recruiting
Locations:
Belgium, Canada, France, Germany, Italy, Netherlands, Poland, South Korea, UK
Identifier:
NCT05575011

Community updates & Press releases